Oxaliplatin-Induced Lhermitte's Sign in Gastric Cancer

Overview

Journal Case Rep Oncol Med

Publisher Wiley

Specialty Oncology

Date 2020 Jul 17

PMID 32670652

Citations 1

Authors

Takeshi Okamoto

Koichi Takagi

Katsuyuki Fukuda

Affiliations

Soon will be listed here.

Abstract

A 64-year-old Japanese man with no significant medical history presented with epigastric discomfort of 2-weeks' duration. He was diagnosed with metastatic HER2-positive gastric cancer. Chemotherapy with capecitabine, oxaliplatin, and trastuzumab was initiated. During the eighth cycle, he suddenly complained of electric shock-like pain in both legs upon neck flexion, consistent with Lhermitte's sign. Oxaliplatin was discontinued, and Lhermitte's sign resolved after 3 months. Neurotoxicity is commonly observed in platinum-based chemotherapy, but Lhermitte's sign is rare. This is the first report of oxaliplatin-induced Lhermitte's sign in a gastric cancer patient.

Citing Articles

Oxaliplatin-Induced Neuropathy: Genetic and Epigenetic Profile to Better Understand How to Ameliorate This Side Effect.

Branca J, Carrino D, Gulisano M, Ghelardini C, Di Cesare Mannelli L, Pacini A Front Mol Biosci. 2021; 8:643824.

PMID: 34026827 PMC: 8138476. DOI: 10.3389/fmolb.2021.643824.

References

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M . OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006; 24(3):394-400. DOI: 10.1200/JCO.2005.03.0106. View

Ciucci G, De Giorgi U, Leoni M, Bianchedi G . Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient. Eur J Neurol. 2003; 10(3):328-9. DOI: 10.1046/j.1468-1331.2003.00579.x. View

Park S, Lin C, Krishnan A, Goldstein D, Friedlander M, Kiernan M . Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity. Oncology. 2009; 77(6):342-8. DOI: 10.1159/000265940. View

Vollmer T, Brass L, Waxman S . Lhermitte's sign in a patient with herpes zoster. J Neurol Sci. 1991; 106(2):153-7. DOI: 10.1016/0022-510x(91)90252-3. View

Nikolaou V, Syrigos K, Saif M . Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016; 15(12):1625-1633. DOI: 10.1080/14740338.2016.1238067. View

Saif M, Reardon J . Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2008; 1(4):249-58. PMC: 1661634. View

Khare S, Seth D . Lhermitte's Sign: The Current Status. Ann Indian Acad Neurol. 2015; 18(2):154-6. PMC: 4445188. DOI: 10.4103/0972-2327.150622. View

Hilkens P, Verweij J, Stoter G, Vecht C, van Putten W, van den Bent M . Peripheral neurotoxicity induced by docetaxel. Neurology. 1996; 46(1):104-8. DOI: 10.1212/wnl.46.1.104. View

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

10.

Walther P, Rossitch Jr E, Bullard D . The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer. 1987; 60(9):2170-2. DOI: 10.1002/1097-0142(19871101)60:9<2170::aid-cncr2820600909>3.0.co;2-n. View

11.

Grisold W, Cavaletti G, Windebank A . Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012; 14 Suppl 4:iv45-54. PMC: 3480245. DOI: 10.1093/neuonc/nos203. View

12.

Gemici C . Lhermitte's sign: Review with special emphasis in oncology practice. Crit Rev Oncol Hematol. 2009; 74(2):79-86. DOI: 10.1016/j.critrevonc.2009.04.009. View

13.

Ordi-Ros J . Lhermitte's sign in systemic lupus erythematosus. Lupus. 1995; 4(4):327. DOI: 10.1177/096120339500400418. View

14.

Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G . Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94(9):2434-40. DOI: 10.1002/cncr.10500. View

15.

Ohsawa M, Otake S, Murakami T, Yamamoto S, Makino T, Ono H . Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice. J Pharmacol Sci. 2014; 125(3):292-9. DOI: 10.1254/jphs.14058fp. View

16.

Ciampi de Andrade D, Teixeira M, Galhardoni R, Ferreira K, Braz Mileno P, Scisci N . Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist. 2017; 22(10):1154-e105. PMC: 5634769. DOI: 10.1634/theoncologist.2017-0235. View

17.

Heinzlef O, Lotz J, Roullet E . Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998; 64(5):667-9. PMC: 2170092. DOI: 10.1136/jnnp.64.5.667. View

18.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

19.

Beckmann Y, Ozakbas S, Bulbul N, Kosehasanogullari G, Secil Y, Bulut O . Reassessment of Lhermitte's sign in multiple sclerosis. Acta Neurol Belg. 2015; 115(4):605-8. DOI: 10.1007/s13760-015-0466-4. View

20.

Newton H, Rea G . Lhermitte's sign as a presenting symptom of primary spinal cord tumor. J Neurooncol. 1996; 29(2):183-8. DOI: 10.1007/BF00182142. View